With the recent success of checkpoint inhibitors and other immunomodulating agents, there has been renewed interest in the combination of such agents with radiation. The biologic premise behind such a strategy is that the tumor-antigen release achieved by localized radiation will promote specific tumor targeting by the adaptive immune system, which can be augmented further by systemic immune-stimulating agents. In this manner, clinicians hope to induce a phenomenon known as the abscopal effect, whereby localized radiation results in immune-mediated tumor regression in disease sites well outside of the radiation field. Herein, we present a comprehensive overview of the early clinical and preclinical evidence behind this approach. Cancer Immunol Res; 2(9); 831-8. Ó2014 AACR.
Introduction
Immunomodulation as a means of cancer therapy has been studied in laboratory settings for many years. Cancer cells are known to have the ability to evade immunosurveillance through a variety of different mechanisms, including reduced expression of tumor antigens, downregulation of MHC class I and II molecules for reduced tumor antigen presentation, secretion of immunosuppressive cytokines such as TGFb, recruitment or induction of immunosuppressive cells such as regulatory T cells (Treg) or myeloid-derived suppressor cells (MDSC), and overexpression of certain ligands [e.g., programmed death ligand-1 (PD-L1)] that inhibit the host's existing antitumor immunity. Recent advances in melanoma research have led to the development of immunotherapies that have substantial antitumor effects in other cancers, including lymphoma, renal cell carcinoma, and non-small cell lung cancer (NSCLC; refs. [1] [2] [3] [4] [5] . These advances have been paradigm shifting for several reasons. First, the observed immune response patterns have led to marked tumor regression that often outlasted the period of study (5, 6) . These responses are unprecedented for such a treatment-refractory patient population. Second, these new forms of immunotherapy have shown activity in tumors traditionally viewed as unresponsive to immune therapies, raising hope that any type of cancer might be "targetable" by immunotherapies if the right agent can be found. This antitumor activity has been most impressive in NSCLC (7) , particularly among patients with unresectable disease treated with primary radiotherapy, a modality hypothesized to stimulate antigen production (8) . It is conceivable that radiotherapy treatment acts as an "in situ vaccine" to prime the immune response. Nascent preclinical and early clinical findings have supported this possibility, suggesting that radiation, through its immune-stimulating properties, may be used as a systemic therapy in addition to a means of local tumor control (1, 4, 9, 10) .
Early in the history of immunomodulation and immunotherapy, irradiated tumor cells that had been engineered to secrete granulocyte-macrophage colony-stimulating factor were used broadly as anticancer vaccines for metastatic melanoma (11) . The intent was to activate T cells that had been inactivated by the tumor's immunosuppressive mechanisms (12) . This nonspecific "shotgun" method occasionally caused tumor regression but did not provide clinical benefit consistently. Early vaccine trials focused on activating T cells without fully understanding the inhibitory pathways that control T-cell responses. The first molecule identified on T cells as an inhibitory checkpoint was cytotoxic T-lymphocyte antigen-4 (CTLA-4; ref. 5). Leach and colleagues showed that CTLA-4 was a critical inhibitory molecule that controlled T-cell responses, thus preventing prolonged immune responses that could be detrimental to normal tissues. These investigators from the Allison laboratory showed that an antibody blocking CTLA-4 elicited tumor regression in murine models (14) . As a result, an antibody to human anti-CTLA-4 was developed, and its clinical success (15, 16 ) opened a new field termed "immune checkpoint targeting." Because of the groundwork laid by studies using anti-CTLA-4 mAbs, and an improved understanding of how T-cell pathways could be targeted to promote antitumor T-cell responses, there was rapid development of additional antibodies to target T-cell pathways. Recently, antibodies targeting another inhibitory T-cell pathway known as PD-1/PD-L1 or PD-L2 have also shown clinical benefit (3, 17) . Furthermore, results from a combination therapy study showed that anti-CTLA-4 plus anti-PD-1 provided even greater clinical benefit than either alone as monotherapy (5) . These so-called checkpoint inhibitors (anti-CTLA-4, anti-PD-1, and anti-PD-L1/L2) have led to renewed enthusiasm for immunotherapy as a treatment modality (12, 18, 19) .
These antibodies were tested initially as monotherapy, but over time, various combinations of these immunotherapeutic agents with current cytotoxic therapies have been investigated both in preclinical tumor models and in clinical trials. Recent studies of radiotherapy combined with immunotherapy have produced promising outcomes in animal models of various types of cancer. However, a considerable amount of work remains to be done to create successful combinations of immunotherapeutics and radiation, which includes identifying the optimal radiation dose, fractionation, and sequence for use in combination with immune checkpoint inhibitors. This Crossroads article addresses the current understanding of these topics and highlights future directions for research.
Radiation in the Treatment of Solid Tumors
Historically, radiation was used as a therapy for the majority of locally advanced solid tumors that are too extensive to be surgically resected. The noninvasive nature of radiation also quickly led to its becoming the de facto standard for patients whose age or general health status would make surgery risky. The technologies associated with tumor imaging and delineation have advanced greatly over the past two to three decades with the advent of new applications such as positron emission tomography and endobronchial ultrasonography. Such advances, in combination with similar advances in radiation planning and delivery, such as the use of four-dimensional computed tomography (CT) to assess and account for tumor motion and intensity-modulated radiotherapy, have led to substantial improvements in the conformality of the radiation dose being delivered to the tumor. One example of this is in early-stage lung cancer with the advent of stereotactic ablative radiotherapy (20, 21) , which incorporates on-board imaging, management of tumor motion, and the highly precise delivery of relatively large radiation fractions. Findings from prospective trials have demonstrated that using this form of radiotherapy for tumors located in the periphery of the lung can lead to 3-year local control rates of more than 98% (22) . Successes such as these, in combination with the benefit of this modality being noninvasive, have led to the emergence of radiotherapy as a key means of achieving local control of lung cancer. Radiation also has an integral role in the treatment of advanced cancers with involvement of mediastinal lymph nodes, often making complete surgical resection difficult. However, although radiation offers clear benefits in terms of both local control and survival, disease recurrence outside the radiation field remains all too common, and most patients eventually die from progressive metastatic disease.
Moreover, despite the known benefit of ionizing radiation in local tumor control, it also enhances the release of cytokines such as TGFb, a known inducer of tumor invasion and the epithelial-mesenchymal transition (23) (24) (25) . On the other hand, radiation can also promote immune responses through the induction of neoantigens and the stimulation of factors such as IFNg that can enhance T-cell infiltration (26) . This dual ability to control local tumor progression and to influence metastatic spread and immune response constitutes a compelling argument for including radiation in combination with the current arsenal of immune checkpoint inhibitors now entering the clinic.
The Abscopal Effect
The abscopal effect refers to the ability of radiation delivered to a local site to minimize or eradicate metastases at distant sites. Although this phenomenon is not often described, it has led to complete regression of metastases at several anatomic sites in patients with cancer (10, 27) . Preclinical studies have provided insight on how localized radiotherapy can induce the abscopal effects and have implicated the immune system as a crucial mediator (reviewed by Frey and colleagues in ref. 28 ). Figure 1 is a schematic diagram outlining the antitumor activity including the abscopal effect in combining radiotherapy with checkpoint immunotherapy. Local radiotherapy damages DNA within tumor cells, leading to tumor-cell apoptosis/necrosis. Tumor antigens released from the dying tumor cells potentially can provide antigenic stimulation that induces antitumorspecific immune responses. This hypothesis is supported by the lack of the abscopal effect of radiotherapy in T celldeficient (nude) mice or in mice with CD8 þ T-cell depletion (29) (30) (31) . Demaria and colleagues (29) reported that the abscopal effect was tumor specific in an elegant study. They administered the dendritic cell growth factor Flt3-L to mice that were implanted in one flank with mammary 67NR tumor cells alone and in the contralateral flank with both 67NR tumor cells and A20 lymphoma cells. They irradiated the flank with only the 67NR tumor cells, which led to significant regression in the contralateral flank of the nonirradiated 67NR tumors but did not affect the growth of the antigenically unrelated A20 lymphoma (29) . In contrast, Camphausen and colleagues (32) found that irradiating Lewis lung carcinoma cells restricted the growth of nonirradiated T241 (fibrosarcoma) cells that had been inoculated in a second site, suggesting that the abscopal effect of radiotherapy can also be mediated through other nontumor-specific mechanisms, or that these two tumors are antigenically related. The systemic increase of many proinflammatory cytokines and chemokines after radiation, from both immune cells and tumor tissues, could account for the nonspecific eradication of distant tumors and metastases (33) . Alternatively, the release of low-affinity tumor antigens prompted by local radiotherapy may also stimulate the release of cross-reactive tumor antigens. Abscopal effects seem to depend on both the radiation dose and the delivery schedule for different types of tumors. In one mouse model involving the Lewis lung carcinoma and a murine fibrosarcoma, low-dose irradiation (2-Gy fractions given twice daily for 6 days) reduced the abscopal effect that had been evident after five daily fractions of 10 Gy each (32). Lee and colleagues (34) reported that a single ablative dose of radiation (20 Gy) to murine B16 melanoma generated a strong antitumor T-cell response that was diminished by the use of fractionated radiotherapy or the addition of chemotherapy agents. In contrast, the combination of an antibody to CTLA-4 and fractionated radiation (but not single-dose irradiation) resulted in abscopal effects in preclinical models of breast and colon cancer (35) . Although radiotherapy causes tumor-cell apoptosis/necrosis, radiation alone is not sufficient to trigger antigenic signals, and a second costimulatory signal is required to elicit systemic antitumor immune responses, especially in poorly immunogenic cancers (30) . Moreover, radiotherapy alone can suppress the growth of primary breast, colon, and lung cancer tumors but not the appearance of lung metastasis in mouse models (30, 35, 36) . Thus, the combination of radiotherapy with immune modulators may have the capability to escalate antitumor responses to a level that could suppress or eliminate systemic metastasis.
Immune Checkpoint Inhibitors
During the past decade, the framework for treating systemic disease has gradually shifted from the broad approach of treating all dividing cells, especially tumor cells, to potentiating the immune system. Immunomodulators that target T-cell surface proteins have shown promise in mobilizing immune cells from a state of anergy to activation in response to the presence of cancer cells. Two T-cell surface proteins, CTLA-4 and PD-1, serve as "immune checkpoints" for T cells (37) ; when CTLA-4 or PD-1 interact with their cognate ligands, an inhibitory signal is conveyed to T cells, resulting in decreased cytokine production, inhibition of proliferation, and reduced cytotoxic function (38, 39) . CTLA-4 is activated by binding to B7-1 (CD80) or B7-2 (CD86), which are expressed predominantly by antigen-presenting cells (APC; ref. 39) . PD-1 is activated through its interaction with PD-L1 and PD-L2, which are present on APCs, on nonneoplastic tumor stroma, and on tumor cells (38) . Although the roles of these immune recognition molecules have been studied extensively in the context of host-pathogen defenses and autoimmune diseases, their roles in suppressing antitumor T-cell responses are now beginning to be understood. Evidence is mounting that during cancer development, ligands for both immune-inhibitory molecules are upregulated in tumor-associated immune cells, in the surrounding tumor stromal environment, and in the tumor (37, 40, 41) . Tumor cells capitalize on these immune tolerance mechanisms to facilitate their growth.
A humanized anti-CTLA-4 IgG 1 antibody, ipilimumab, has been tested in several multi-institutional, randomized control trials. Most of these studies have focused on patients with stage III or IV melanoma, for whom the prognosis is poor and few therapeutic options are available (42). Hodi and colleagues (15) reported the results of a randomized, phase III clinical trial of 676 patients with melanoma, who received ipilimumab with or without gp100, a well-studied cancer vaccine derived from the melanoma glycoprotein 100. These investigators showed that the groups treated with ipilimumab alone or with ipilimumab plus gp100 had better overall survival (the primary study endpoint) than those treated with gp100 alone (15) . This was the first phase III randomized clinical trial to report a survival benefit for patients with melanoma. In a second phase III randomized clinical trial, Robert and colleagues (16) assigned 502 patients with previously untreated stage III or IV melanoma to receive dacarbazine, a chemotherapy agent approved by the FDA for advanced melanoma (43), or dacarbazine plus ipilimumab. The combination of dacarbazine plus ipilimumab led to improved overall survival relative to dacarbazine alone. In addition to melanoma, ipilimumab has been tested in phase I and II trials for other solid malignancies, including small-cell lung cancer (44) , NSCLC (45), bladder cancer (46), pancreatic cancer (47), prostate cancer (48) , and renal cell carcinoma (49). Lynch and colleagues (44) reported the results of a randomized phase II trial of 204 patients, who received paclitaxel and carboplatin either with or without ipilimumab, administered concurrently or in a phased manner, with alternating cycles of chemotherapy and ipilimumab. Patients treated with ipilimumab administered in a phased manner, not concurrently with chemotherapy, had significantly better progression-free survival (PFS), providing evidence supporting sequenced therapy (44) . A new phase III trial of 908 patients with squamous NSCLC and using a similar design has begun recently (ClinicalTrials.gov number NCT01285609).
On the basis of the success of anti-CTLA-4 cancer immunotherapy, other antibodies have been developed to target additional T-cell molecules, including those involved in the PD-1 signaling pathway. Several large multiinstitution trials have tested the use of these antibodies for various types of cancer. In two clinical studies for patients with advanced solid malignancies, Topalian and colleagues (17) tested the anti-PD-1 antibody nivolumab in 296 patients, and Brahmer and colleagues (3) tested an anti-PD-L1 antibody (BMS-936559) in 207 patients. Significant objective response rates were observed against melanomas, NSCLC, and renal cell carcinoma in both trials, and the anti-PD-1 antibody seemed to elicit higher response rates (17) . Particularly notable was the response rate in NSCLC (5 of 49), which, unlike melanoma and renal cell carcinoma, was historically considered unresponsive to immunotherapy (7) . This finding suggests that our previous way of defining cancers as "immunogenic" versus "nonimmunogenic" was incorrect and, in reality, many types of cancer can be treated with immunotherapy if we use the appropriate agents to overcome the inhibitory pathways that exist within the immune system. As a result, multiple trials are now testing anti-PD-L1 or PD-1 antibodies in patients with solid tumors.
Because CTLA-4 provides inhibitory signals to T cells by binding to B7 molecules, which blocks appropriate costimulation of T cells by CD28 (13) , and PD-1 provides inhibitory signals to T cells by interfering with T-cell receptor signaling, Curran and colleagues (50) tested the combination of anti-CTLA-4 plus anti-PD-1 in tumor-bearing mouse models and showed improved antitumor responses in the combination therapy compared with monotherapy. As predicted by the murine studies, a phase I clinical trial combining anti-CTLA-4 and anti-PD-1 was reported to provide dramatic antitumor responses in patients with metastatic melanoma. Wolchok and colleagues (5) administered nivolumab and ipilumumab to patients with advanced melanoma and found that the 53 patients given the two-drug regimen had a higher objective response rate than did patients treated with either antibody alone. Moreover, many of these patients achieved "deep" responses, with greater than 80% tumor reduction that lasted for extended periods (5). In another study, Hamid and colleagues (6) used a different humanized anti-PD-1 antibody, lambrolizumab, in 135 patients with melanoma and reported a high rate of sustained tumor regression, with no difference in response among patients who had or had not received prior ipilumumab therapy. Together, results from these two trials suggest that concurrent-but not sequential-use of anti-CTLA-4 and anti-PD-1 drugs can have clinically complementary effects.
Combining Immune Checkpoint Inhibitors with Radiation
Although anti-CTLA-4 and anti-PD-1 mAbs may overcome T-cell suppression, T-cell activation depends on the engagement of the antigen receptor and the activating costimulation molecule CD28 expressed by mature APCs (39) . For this reason, ionizing radiation, which can increase the production and presentation of tumor antigens not only by immunogenic cancers like melanoma but also by poorly immunogenic tumors, could augment the antitumor immune responses elicited by checkpoint immunomodulators anti-CTLA-4 and anti-PD-L1 (30, 51, 52) . Radiation may augment immunomodulation by increasing CTL activity and the antigenic peptide pool (4, 51) . New data from Deng and colleagues (53) suggests that the combination of radiation and PD-L1 checkpoint blockade can synergistically reduce MDSCs. Preclinical studies of murine models have demonstrated that Anti-CTLA-4 and radiation: preclinical findings In the first preclinical study of the CTLA-4 blocker ipilimumab in combination with radiation, Demaria and colleagues (30) tested the hypothesis that ipilimumab in combination with radiotherapy could elicit an abscopal antitumor response in a model of metastatic 4T1 breast cancer. In that study, tumors were injected in a primary and a distant site in mice and, as expected, ipilimumab alone did not stop the progression of this poorly immunogenic tumor. Similarly, although radiation alone delayed the growth of primary tumors, irradiated and control IgG-treated mice had similar OS rates owing to distant lung metastasis. However, mice that received the combined regimen of CTLA-4 blockade and local radiotherapy showed both tumor shrinkage and inhibition of lung metastasis, which was associated with a significant survival advantage (30) . A similar study combining Flt3 therapy with radiation conducted with metastatic lung cancer cells in a tumor model produced the same results and suggested a longterm protective immune response (36) . In another study of breast cancer cells, Mastsumura and colleagues provided the first evidence that T-cell recruitment by proinflammatory chemotactic factors overcame previous blocks at the effector phase by poorly immunogenic tumors (56) . This study confirmed that the expansion of vaccine-specific T cells via the use of mAbs was not sufficient to elicit an antitumor immune response (57, 58) . Rather, the chemokines and their receptors induced by ionizing radiation were needed to recruit tumorspecific CTLs to the target (59) and, together with CTLA-4 blockers, break the pattern of immune escape and tumor tolerance by lymphocytes. Ruocco and colleagues (60) reported that in mice anti-CTLA-4 mAbs used as monotherapy did not induce effective immune responses to poorly immunogenic tumors but it did when combined with local radiation, confirming the role of ipilimumab and radiation in overcoming the tumor-elicited MHC class I-dependent arrest. Although relatively immunogenic tumors such as melanoma have shown regression after antibody therapy (15) , poorly immunogenic tumors may need the priming effects of radiotherapy to overcome blocks at the effector level (9, 30) . In other words, expansion of vaccine-specific T cells by CTLA-4 blockade alone may not be sufficient (57, 58, 61) .
Anti-CTLA-4 and radiation: clinical findings
Postow and colleagues (10) describe a patient whose metastatic melanoma regressed upon treatment with ipilimumab and concurrent palliative radiotherapy. Specifically, a CT scan obtained several months after the patient had received a 28.5-Gy radiation dose (given in three 9.5-Gy fractions) to an area next to the spine revealed that masses elsewhere in the spleen and hilar lymph nodes had also regressed and eventually reached the point of stable minimal disease 10 months after the last dose of radiation. This case led to a pilot study at a different institution by Hiniker and colleagues (55) to combine ipilimumab and concurrent radiotherapy for a patient with asymptomatic melanoma. That patient was given a higher radiation dose (54 Gy in three fractions) and showed a complete response in both the primary tumor and the metastatic lesions, which confirms the findings from preclinical studies indicating the importance of radiation dose (9, 35) . These results have led to interest in combining ipilimumab with radiation for treatment of other cancers, and a recent case report described a patient with NSCLC who also had an abscopal response (27) .
In a phase I/II clinical study, Slovin and colleagues (48) found that patients with metastatic castration-resistant prostate cancer responded to ipilimumab plus radiation. In that study of 50 men given ipilimumab (four 10-mg/kg doses) plus radiation (8-Gy fractions to each lesion for 3 weeks), 1 patient experienced a complete response, 6 had disease stabilization, and 8 showed declines in prostatespecific antigen levels that mirrored findings from previous preclinical studies. This combination is now being tested in phase III trials, and interest has been spurred in its use to treat other types of tumors.
Anti-PD-1 and radiation: preclinical findings
With the anticancer efficacy of CTLA-4 blockers, anti-PD-1/-PD-L1 mAbs have drawn much interest for their potential use in lung or colon cancer (62) and in combination with CTLA-4 blockade for melanoma (5, 6) . The mechanism by which radiation augments the therapeutic effects of the anti-PD-1/PD-L1 mAbs was elucidated in a preclinical study of triple-negative breast cancer. In this study, neither anti-PD-1 mAb nor radiation when given alone was effective in a murine model of triple-negative breast cancer. However, the addition of anti-PD-1 mAbs enhanced the curative capacity of radiotherapy and a-CD137 (an agonist antibody for costimulatory molecule 4-1BB) against both established tumors and secondary tumor challenge, indicating that the combined regimen conferred antitumor immune responses and memory (63) . Moreover, a subset of tumor-specific CD8 þ T cells expressing CD137, PD-1, or both was found to persist in the irradiated tumor tissues, suggesting that the synergistic effect of this triple combination was mediated by an activation or escalation of CD8 þ T cell-mediated antitumor responses (63) . Although the PD-1 axis did not seem to be the main contributor to the metastatic and neoplastic capability of AT-3 tumors, PD-1 signaling within those tumors was critical for limiting the effectiveness of a-CD137/a-CD40 immunotherapy, with or without adjuvant radiotherapy (63) . Indeed, the combination of a-CD137, anti-PD-1, and radiation showed greater efficacy (40% rejection) than anti-PD-1 or radiation, given alone or in combination (63) . Furthermore, in mice whose tumors regressed completely at the primary site when treated with this triple combination, growth of the AT-3 tumors at distant sites was also impaired, indicating an abscopal effect. This effect was dependent on the presence of CD8 þ T cells, as mice lacking CD4 þ T cells showed the abscopal effect, but CD8 þ T cell-depleted mice did not (63) .
Results of a preclinical study of murine intracranial glioma treated with anti-PD-1 mAbs plus radiotherapy showed not only long-term survival of the treated mice, but also robust systemic immunologic memory in the surviving mice, as they were able to reject a secondary challenge of glioma cells injected in the flank (18) . Specifically, median survival periods were similar for control mice (25 days) and mice given only anti-PD-1 mAbs (27 days) or radiation (28 days). However, the combination of radiation plus anti-PD-1 therapy extended the median survival to 53 days (P < 0.05 by log-rank Mantel-Cox test), and 15% to 40% of mice survived more than 180 days after treatment (18) . The combination therapy increased tumor infiltration by CD8
þ CTLs and decreased the number of CD4 þ Tregs. Finally, in a test of immunologic memory, na€ ve and long-term surviving mice were injected in the flanks with GL261-luc cells. All 8 na€ ve mice died from the growth of the challenged glioma cells, whereas mice that received prior treatment with the combined regimen rejected the glioma challenge (18) . On the basis of the results of these preclinical studies, several clinical trials have been initiated to assess the efficacy of combining anti-PD-1 immunotherapy with radiotherapy. Reports of toxicity associated with immune checkpoint inhibitors in completed trials are summarized below.
Toxicity of Immune Checkpoint Inhibitors
Perhaps not surprisingly, rates of immune-related adverse events were high in the clinical trials completed to date. Although most of these adverse events were mild (grade 1-2), some were severe, and a few were lethal. The most common toxic effects were considered to be immunologic in origin, and the sites most commonly affected were the skin, gastrointestinal system, liver, and lung (3, 5, 6, 16, 17) .
Of particular importance for trials aiming to explore abscopal effects is the risk of radiation pneumonitis, especially for patients with thoracic disease. Rates of severe adverse events (grade 3-4), including pneumonitis, dyspnea, or cough, have ranged from 2% to 4% (5, 6, 15, 17) among patients treated with agents targeting CTLA-4 and PD-1, and were believed to contribute to 3 deaths in one study (17) and 1 death in another study (6) . Radiation pneumonitis is thought to reflect an immune-mediated inflammatory reaction to radiationinduced lung damage (64, 65) . Severe forms can be lethal, and thus radiation pneumonitis is often considered as a radiation dose-limiting toxicity (66) . Results from retrospective analyses have indicated that the conformality of the radiation dose to be delivered is crucial to minimizing toxicity, and indeed significant reductions in toxicity have been achieved with the use of more sophisticated radiation planning and treatment modalities, such as protons (66) (67) (68) . Similarly, radiation treatment in the abdomen that could result in bowel radiation could similarly exacerbate colitis. Thus, trials combining checkpoint immunotherapy with radiation for solid tumors must be conducted with great care, and with strict limits placed on the amounts of normal lung, bowel, and other tissues that are exposed to radiation via the use of lung dose-volume histograms. Interestingly, immunotherapy with PD-L1 inhibitors was associated with much lower pneumonitis rates than the rates with PD-1 inhibitors (69) . A final precaution is the need to account for both acute and late toxicity in designing trials. Most phase I trials involving radiation allow dose escalation based on the appearance of acute toxicity; however, pneumonitis often does not appear until several months after radiation treatment is completed, and thus the follow-up period must be considerably longer before dose escalation should be considered.
Conclusions
Cancer immunotherapy has come of age and is becoming one of the pillars, along with surgery, chemotherapy, and radiotherapy, for the treatment of patients with cancer. Combination therapies are also being investigated, including inhibition of both CTLA-4 and PD-1, or use of one immunotherapy agent with chemotherapy or with other molecular-targeted agents. Although such combinations may improve antitumor efficacy, their toxicity may prove to be a major obstacle. In contrast, combinations of radiation (preferably stereotactic ablative radiotherapy) with immune checkpoint inhibitors have the advantage that radiation can provide local control and may also prompt the release of tumor antigens that activate immune response and enhance immune recognition on a systemic level. Many questions remain, including how to minimize overlapping toxic effects of radiation and immunotherapy, and how to optimize the sequencing of these two treatment modalities. Although only a limited number of patients have been treated with this approach, these early results are promising and warrant further investigation with a cautious eye on safety and toxicity.
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